
BiotechTV - News ASCO 2025: Candel Therapeutics CEO Paul Peter Tak describes phase 3 prostate cancer data from the company's off-the-shelf, adeno delivered, cancer immunotherapy
Jun 2, 2025
Chapters
Transcript
Episode notes

BiotechTV - News